Bold Therapeutics公司的临床阶段抗癌药物BOLD-100展示了对化疗引起的周围神经病变的保护作用-动脉网

Bold Therapeutics' Clinical-Stage Anticancer Agent BOLD-100 Demonstrates Protective Effects Against Chemotherapy-Induced Peripheral Neuropathy

PR Newswire 等信源发布 2026-04-16 20:38



可切换为仅中文







VANCOUVER, BC

加拿大温哥华

，

April 16, 2026

2026年4月16日

/PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company that was founded to develop and commercialize novel metallotherapeutics, has shared new data highlighting the ability of its lead asset, BOLD-100, to demonstrate protective effects against chemotherapy-induced peripheral neuropathy..

/PRNewswire/ -- Bold Therapeutics是一家临床阶段的生物制药公司，致力于开发和商业化新型金属治疗药物，该公司分享了新的数据，强调其主要资产BOLD-100能够展示出对化疗引起的周围神经病变的保护作用。

BOLD-100 is a first-in-class, ruthenium-based anticancer agent in Phase 2 clinical development for advanced gastrointestinal (GI) cancers in combination with the chemotherapy regimen FOLFOX. BOLD-100 plus FOLFOX improves overall survival and progression-free survival in patients, including advanced colon (mCRC), gastric (GC), and bile duct cancers (BTC).

BOLD-100 是一种首创的、基于钌的抗癌药物，目前正处于针对晚期胃肠道 (GI) 癌症的二期临床开发阶段，并与化疗方案 FOLFOX 联合使用。BOLD-100 加上 FOLFOX 可改善患者的总体生存期和无进展生存期，包括晚期结肠癌 (mCRC)、胃癌 (GC) 和胆管癌 (BTC)。

While FOLFOX is a standard-of-care therapy for GI cancers, its clinical utility is limited by acute and chronic peripheral neuropathies which present in the majority of patients. Remarkably, in the ongoing Phase 2 development of BOLD-100, significantly lower than expected incidence of oxaliplatin-induced peripheral neuropathy (OIPN) was observed in patients treated with BOLD-100 plus FOLFOX.

虽然FOLFOX是胃肠道癌症的标准治疗方案，但其临床应用受到急性及慢性周围神经病变的限制，这些症状在大多数患者中都会出现。值得注意的是，在BOLD-100的二期临床开发中，接受BOLD-100联合FOLFOX治疗的患者中观察到的奥沙利铂诱导的周围神经病变（OIPN）发生率显著低于预期。

Compared to FOLFOX alone historical benchmarks, BOLD-100 plus FOLFOX any-grade neuropathy was:.

与单独使用FOLFOX的历史基准相比，BOLD-100加FOLFOX的任何级别神经病变是：。

Colorectal Cancer

结直肠癌

; 14% vs 53% benchmark

；14% 对 53% 基准

Biliary tract cancer;

胆道癌；

35% vs 58% benchmark

35% 对 58% 基准

Gastric Cancer;

胃癌；

19% vs 63% benchmark

19% 对 63% 基准

'These clinical findings are promising given the prevalence of peripheral neuropathy among patients undergoing chemotherapy,' said Mark Bazett, PhD, Senior Director of Preclinical Development. 'The potential to improve patient outcomes while simultaneously improving quality of life is a key differentiating characteristic of BOLD-100.

“鉴于接受化疗的患者中周围神经病变的普遍性，这些临床发现很有前景，”Mark Bazett博士，临床前开发高级总监说道，“在提高患者疗效的同时改善生活质量，是BOLD-100的一个关键区别特征。”

Our upcoming AACR presentation validates these important results in a range of preclinical models, and provides mechanistic understanding.'.

我们即将在AACR上展示的报告验证了这些在多种临床前模型中的重要结果，并提供了机制上的理解。

Bold Therapeutics will be attending the American Association for Cancer Research (AACR) Annual meeting later this month in San Diego from April 17-22, where they will present advanced i

Bold Therapeutics 将于本月晚些时候参加在美国圣地亚哥举行的美国癌症研究协会 (AACR) 年会，会议时间为 4 月 17 日至 22 日，届时他们将展示先进的...

n vivo

在体内

and

和

in vitro

体外

preclinical modelling of BOLD-100's neuroprotection, along with mechanism of action data.

BOLD-100的神经保护临床前模型，以及作用机制数据。

Abstract Title

摘要标题

: Clinical-stage Anticancer Agent BOLD-100 Demonstrates Protective Effects Against Chemotherapy-Induced Peripheral Neuropathy

临床阶段抗癌药物BOLD-100显示出对化疗引起的周围神经病变的保护作用

Session Time

会话时间

: April 21, 2:00 PM - 5:00 PM

：4月21日，下午2:00 - 下午5:00

Location

位置

: Poster Section 14; Poster Board 11

：海报部分14；海报板11

Presentation Number

演示编号

: 5753

Abstract link:

抽象链接：

https://aacrjournals.org/cancerres/article/86/7_Supplement/5753/778155

Bold Therapeutics is currently advancing BOLD-100 through a global Phase 2 randomized controlled trial across sites in Canada, European Union, and South Korea. This trial is investigating BOLD-100's anticancer efficacy but also includes important quality of life questionnaires focused on its neuroprotective potential.

Bold Therapeutics公司目前正在加拿大、欧盟和韩国的多个中心推进BOLD-100的全球II期随机对照试验。该试验不仅研究BOLD-100的抗癌功效，还包括重要的生活质量问卷，重点关注其神经保护潜力。

Please visit .

请访问。

ClinicalTrials.gov

临床试验.gov

for more information (NCT04421820).

更多信息（NCT04421820）。

For more information or for interest in investing, please visit the Company's website at

欲了解更多信息或有兴趣投资，请访问公司网站

https://www.bold-therapeutics.com/

Contact: Jim Pankovich, EVP

联系人：Jim Pankovich，执行副总裁